VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis.

MLA

Sivaraja, Mohanram, et al. “VE-1902-A Direct Thrombin Inhibitor with Reversible Covalent Mechanism of Action Shows Efficacy with Reduced Bleeding in Rodent Models of Thrombosis.” Thrombosis Research, vol. 190, June 2020, pp. 112–21. EBSCOhost, https://doi.org/10.1016/j.thromres.2020.04.020.

APA

Sivaraja, M., Clemens, D. M., Sizikov, S., Dash, S., Xu, C., Rienzo, M., Yang, B., Ryan, M., Chattopadhyay, M., Igoudin, L., Chang, S. S., Keutzer, S., Zalicki, P., Estiarte, M. A., Shiau, T. P., Short, K. M., Williams, D. C., Datta, A., Pozzi, N., … Kita, D. B. (2020). VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. Thrombosis Research, 190, 112–121. https://doi.org/10.1016/j.thromres.2020.04.020

Chicago

Sivaraja, Mohanram, Daniel M Clemens, Sivan Sizikov, Subhadra Dash, Chengpei Xu, Matthew Rienzo, Bo Yang, et al. 2020. “VE-1902-A Direct Thrombin Inhibitor with Reversible Covalent Mechanism of Action Shows Efficacy with Reduced Bleeding in Rodent Models of Thrombosis.” Thrombosis Research 190 (June): 112–21. doi:10.1016/j.thromres.2020.04.020.